The goal of the CWRU/UHC CFAR Development Core (Core B) is to stimulate AIDS-related research at CWRU and its affiliates by providing resources to enhance research opportunities. This goal will be achieved through targeting the following objectives: 1. Enhancing faculty development through the provision of competitive developmental awards 2. Supporting recruitment of new faculty interested in AIDS research 3. Promoting interactions among investigators at CWRU especially across different scientific disciplines and in areas of AIDS research that are currently under-represented at CWRU. During the next period of award, the Developmental Core will support the following programs: 1. Provision of seed funding as developmental awards to develop preliminary data sufficient to attract independent research grants. Seed funding will support as many as 5 research awards of up to $30,000 targeted to support the research initiatives of young investigators each year. This will be supported by CFAR funds. 2. Provision of a mentoring program to support junior faculty and fellows' development as independent investigators. A comprehensive mentoring program will assure that junior investigators benefit from structured mechanisms to enhance the rigor and quality of their research presentations, manuscripts and research grants. 3. Enhancement of faculty recruitment. Substantial funds obtained from institutional sources will be used to help in the recruitment of new faculty interested in AIDS research. Newly recruited faculty will be allowed to apply for an enhanced developmental award of $90,000 over three years paid using institutional funds administered through the CFAR Developmental Core. 4. Enhancement of core facilities. Institutional funds will be used to provide support of key equipment needed to extend and improve the services of CFAR cores. These awards will be recommended by the Steering Committee (see Core A) following a requests from the Core directors that will be evaluated during CFAR strategic planning meetings. 5. Initiation of new AIDS research. Institutional funds will provide developmental grants to support initiation of new research avenues, especially in areas that are currently under represented in the CFAR. A limited number of developmental grants of up to $50,000 will be awarded on a competitive basis using a parallel procedure to that used to evaluate developmental grants but paid for using institutional funds. For each award, objective criteria will be used to monitor progress and evaluate success. For developmental awards and for the mentoring program, annual determination of programmatic successes and failure will be used to modify the program and award criteria to enhance the chances of success.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI036219-13
Application #
7257261
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2006-04-01
Budget End
2007-03-31
Support Year
13
Fiscal Year
2006
Total Cost
$238,675
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Elion, Richard A; Althoff, Keri N; Zhang, Jinbing et al. (2018) Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. J Acquir Immune Defic Syndr 78:62-72
Martinez, Leonardo; Shen, Ye; Handel, Andreas et al. (2018) Effectiveness of WHO's pragmatic screening algorithm for child contacts of tuberculosis cases in resource-constrained settings: a prospective cohort study in Uganda. Lancet Respir Med 6:276-286
Grover, Surbhi; Desir, Fidel; Jing, Yuezhou et al. (2018) Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis. J Acquir Immune Defic Syndr 79:421-429
Kityo, Cissy; Makamdop, Krystelle Nganou; Rothenberger, Meghan et al. (2018) Lymphoid tissue fibrosis is associated with impaired vaccine responses. J Clin Invest 128:2763-2773
Wiredja, Danica D; Tabler, Caroline O; Schlatzer, Daniela M et al. (2018) Global phosphoproteomics of CCR5-tropic HIV-1 signaling reveals reprogramming of cellular protein production pathways and identifies p70-S6K1 and MK2 as HIV-responsive kinases required for optimal infection of CD4+ T cells. Retrovirology 15:44
Oliveira, Vitor H F; Perazzo, Joseph D; Josephson, Richard A et al. (2018) Association Between the 6-Minute Walk Test Distance and Peak Cardiorespiratory Fitness Among People Living with HIV Varies by Fitness Level. J Assoc Nurses AIDS Care 29:775-781
Paparisto, Ermela; Woods, Matthew W; Coleman, Macon D et al. (2018) Evolution-Guided Structural and Functional Analyses of the HERC Family Reveal an Ancient Marine Origin and Determinants of Antiviral Activity. J Virol 92:
Llewellyn, George N; Alvarez-Carbonell, David; Chateau, Morgan et al. (2018) HIV-1 infection of microglial cells in a reconstituted humanized mouse model and identification of compounds that selectively reverse HIV latency. J Neurovirol 24:192-203
Longenecker, Chris T; Sullivan, Claire E; Morrison, Justin et al. (2018) The effects of HIV and smoking on aortic and splenic inflammation. AIDS 32:89-94
Tomas, Myreen E; Mana, Thriveen S C; Wilson, Brigid M et al. (2018) Tapering Courses of Oral Vancomycin Induce Persistent Disruption of the Microbiota That Provide Colonization Resistance to Clostridium difficile and Vancomycin-Resistant Enterococci in Mice. Antimicrob Agents Chemother 62:

Showing the most recent 10 out of 539 publications